Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

NCT03604991 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

SUSPENDED

Status

278

Enrollment

NIH

Sponsor class

Stopped End of Initial Phase of Multi-phase protocol

Conditions

Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
PROCEDURE: Computed Tomography
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
DRUG: Paclitaxel
PROCEDURE: Positron Emission Tomography
RADIATION: Radiation Therapy

Sponsor

National Cancer Institute (NCI)